IP Library › Granted Patent US 12,416,046
Granted Patent B2
US 12,416,046 · App. 18/675,708 · Granted Sep 16, 2025

Labeled nucleotide analogs, reaction mixtures, and methods and systems for sequencing

Inventors: Lubomir Sebo (Redwood City, CA); Gene Shen (Santa Clara, CA); Stephen Yue (Eugene, OR); Honey Osuna (San Francisco, CA); Yuri Lapin (Newark, CA); Louis Brogley (Santa Cruz, CA); Andrei Fedorov (San Bruno, CA)
Assignee: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
C12Q1/6869C07H19/10C07H19/207C07K19/00C09B69/105
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,416,046
App. No.
18/675,708
Granted
Sep 16, 2025
Kind
B2
Abstract

Labeled nucleotide analogs comprising at least one avidin protein, at least one dye-labeled compound, and at least one nucleotide compound are provided. The analogs are useful in various fluorescence-based analytical methods, including the analysis of highly multiplexed optical reactions in large numbers at high densities, such as single molecule real time nucleic acid sequencing reactions. The analogs are detectable with high sensitivity at desirable wavelengths. They contain structural components that modulate the interactions of the analogs with DNA polymerase, thus decreasing photodamage and improving the kinetic and other properties of the analogs in sequencing reactions. Also provided are nucleotide and dye-labeled compounds of the subject analogs, as well as intermediates useful in the preparation of the compounds and analogs. Compositions comprising the compounds, methods of synthesis of the intermediates, compounds, and analogs, and mutant DNA polymerases are also provided.

Claims (49)

1. A labeled nucleotide analog comprising:

a first avidin protein having four subunits, each subunit comprising one biotin binding site;

a first nucleotide compound bound to the first avidin protein, the first nucleotide compound comprising a polyphosphate element, a nucleoside element, an optional multivalent central core element, a terminal coupling element, and a nucleotide linker element, wherein the first nucleotide compound comprises at least one affinity modulating element; and

a first dye-labeled compound bound to the first avidin protein, wherein the first dye-labeled compound is a compound of structural formula (IIIA), (IIIB), (IIIC), (IIID), or (IIIE):

wherein

each L′ is independently a dye compound linker element;

each S is independently a shield element;

each A is independently an acceptor dye;

each D is independently a donor dye;

each B″ is independently a terminal coupling element;

each p is independently 0 or 1; and

each r is independently an integer from 0 to 8;

wherein the compound of structural formula (IIIA), (IIIB), (IIIC), (IIID), or (IIIE) comprises at least one shield element, at least one acceptor dye, and at least one donor dye; and

wherein the at least one shield element does not comprise a protein.

2. The labeled nucleotide analog of claim 1 , wherein each r is independently an integer from 0 to 4.

3. The labeled nucleotide analog of claim 1 , wherein the first dye-labeled compound comprises at least two donor dyes.

4. The labeled nucleotide analog of claim 1 , wherein the first dye-labeled compound comprises at least two acceptor dyes.

5. The labeled nucleotide analog of claim 1 , wherein the first dye-labeled compound comprises at least two donor dyes and at least two acceptor dyes.

6. The labeled nucleotide analog of claim 1 , wherein at least one dye compound linker element comprises a shield element or a side chain element.

7. The labeled nucleotide analog of claim 1 comprising two terminal coupling elements.

8. The labeled nucleotide analog of claim 1 , wherein the terminal coupling element comprises a biotin moiety.

9. The labeled nucleotide analog of claim 8 , wherein the terminal coupling element comprises a bis-biotin moiety.

10. The labeled nucleotide analog of claim 1 , wherein the at least one acceptor dye or the at least one donor dye is a cyanine dye.

11. The labeled nucleotide analog of claim 1 , wherein the first dye-labeled compound does not contain a nucleoside.

12. A labeled nucleotide analog comprising:

a first avidin protein having four subunits, each subunit comprising one biotin binding site;

a first nucleotide compound bound to the first avidin protein, the first nucleotide compound comprising a polyphosphate element, a nucleoside element, an optional multivalent central core element, a terminal coupling element, and a nucleotide linker element, wherein the first nucleotide compound comprises at least one affinity modulating element; and

a first dye-labeled compound bound to the first avidin protein, wherein the first dye-labeled compound is a compound of structural formula (IIIF):

wherein

each L′ is independently a dye compound linker element;

each S is independently a shield element;

each A is independently an acceptor dye;

each D is independently a donor dye;

each B″ is independently a terminal coupling element;

each p is independently 0 or 1; and

each r′ is independently an integer from 0 to 4;

wherein the compound of structural formula (IIIF) comprises at least one shield element, at least one acceptor dye, and at least one donor dye; and

wherein the at least one shield element does not comprise a protein.

13. The labeled nucleotide analog of claim 12 , wherein each r′ is independently an integer from 0 to 2.

14. The labeled nucleotide analog of claim 13 , wherein each r′ is independently 0 or 1.

15. The labeled nucleotide analog of claim 12 comprising at least two donor dyes.

16. The labeled nucleotide analog of claim 12 comprising at least two acceptor dyes.

17. The labeled nucleotide analog of claim 12 comprising at least two donor dyes and at least two acceptor dyes.

18. The labeled nucleotide analog of claim 12 , wherein at least one dye compound linker element comprises a shield element or a side chain element.

19. The labeled nucleotide analog of claim 12 comprising two terminal coupling elements.

20. The labeled nucleotide analog of claim 12 , wherein the terminal coupling element comprises a biotin moiety.

21. The labeled nucleotide analog of claim 20 , wherein the terminal coupling element comprises a bis-biotin moiety.

22. The labeled nucleotide analog of claim 12 , wherein the at least one acceptor dye or the at least one donor dye is a cyanine dye.

23. The labeled nucleotide analog of claim 12 , wherein the first one dye-labeled compound does not contain a nucleoside.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 28, 2024
From: SEBO, LUBOMIR; SHEN, GENE; YUE, STEPHEN; OSUNA, HONEY; LAPIN, YURI; BROGLEY, LOUIS; FEDOROV, ANDREI
To: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Reel/Frame 067541/0187 →
Continuity (5)
Continuation 18045436 · Oct 10, 2022
Continuation 17006669 · Aug 28, 2020
Continuation 15357966 · Nov 21, 2016
Provisional Application 62258416 · Nov 20, 2015
Related Publication 20250002989A1 · Jan 2, 2025
References Cited (85)
US 4711955A · Ward et al. · 1987 [cited by applicant]
US 5223384A · Ohbayashi et al. · 1993 [cited by applicant]
US 5688648A · Mathies et al. · 1997 [cited by applicant]
US 6153442A · Pirio et al. · 2000 [cited by applicant]
US 6255083B1 · Williams · 2001 [cited by applicant]
US 6399335B1 · Kao et al. · 2002 [cited by applicant]
US 6787308B2 · Balasubramanian et al. · 2004 [cited by applicant]
US 6917726B2 · Levene et al. · 2005 [cited by applicant]
US 7013054B2 · Levene et al. · 2006 [cited by applicant]
US 7041812B2 · Kumar et al. · 2006 [cited by applicant]
US 7056661B2 · Korlach et al. · 2006 [cited by applicant]
US 7405281B2 · Xu et al. · 2008 [cited by applicant]
US 7476503B2 · Turner et al. · 2009 [cited by applicant]
US 7767805B2 · Buzby · 2010 [cited by applicant]
US 7777013B2 · Xu et al. · 2010 [cited by applicant]
US 7842475B2 · Zheng et al. · 2010 [cited by applicant]
US 7906284B2 · Turner et al. · 2011 [cited by applicant]
US 7968702B2 · Wegener et al. · 2011 [cited by applicant]
US 7973146B2 · Shen et al. · 2011 [cited by applicant]
US 8058031B2 · Xu et al. · 2011 [cited by applicant]
US 8133672B2 · Bjornson et al. · 2012 [cited by applicant]
US 8133702B2 · Shen et al. · 2012 [cited by applicant]
US 8182993B2 · Tomaney et al. · 2012 [cited by applicant]
US 8236499B2 · Patel et al. · 2012 [cited by applicant]
US 8257954B2 · Clark et al. · 2012 [cited by applicant]
US 9062091B2 · Bjornson et al. · 2015 [cited by applicant]
US 10781483B2 · Sebo · 2020 [cited by examiner]
US 12000000B2 · Sebo · 2024 [cited by examiner]
US 20030077610A1 · Nelson et al. · 2003 [cited by applicant]
US 20030162213A1 · Fuller et al. · 2003 [cited by applicant]
US 20030162216A1 · Gold et al. · 2003 [cited by applicant]
US 20040241716A1 · Kumar et al. · 2004 [cited by applicant]
US 20060281911A1 · Beaucage et al. · 2006 [cited by applicant]
US 20070249652A1 · Parenty et al. · 2007 [cited by applicant]
US 20080076189A1 · Belosludtsev et al. · 2008 [cited by applicant]
US 20090024331A1 · Tomaney et al. · 2009 [cited by applicant]
US 20090118129A1 · Turner · 2009 [cited by applicant]
US 20090142316A1 · Majoral et al. · 2009 [cited by applicant]
US 20090186343A1 · Wang et al. · 2009 [cited by applicant]
US 20090208957A1 · Korlach et al. · 2009 [cited by applicant]
US 20090325260A1 · Otto et al. · 2009 [cited by applicant]
US 20100075328A1 · Bjornson et al. · 2010 [cited by applicant]
US 20100136592A1 · Kong et al. · 2010 [cited by applicant]
US 20100152424A1 · Korlach et al. · 2010 [cited by applicant]
US 20100167299A1 · Korlach · 2010 [cited by applicant]
US 20100221716A1 · Flusberg et al. · 2010 [cited by applicant]
US 20100255488A1 · Kong et al. · 2010 [cited by applicant]
US 20100261185A1 · Nikiforov · 2010 [cited by applicant]
US 20110183320A1 · Flusberg et al. · 2011 [cited by applicant]
US 20110244447A1 · Korlach · 2011 [cited by applicant]
US 20110256618A1 · Eid et al. · 2011 [cited by applicant]
US 20120052506A1 · Yue et al. · 2012 [cited by applicant]
US 20130316912A1 · Bjornson · 2013 [cited by examiner]
US 20150050659A1 · Sebo · 2015 [cited by examiner]
EP 3376997B1 · 2024 [cited by applicant]
WO 1991006678A1 · 1991 [cited by applicant]
WO 1996027025A1 · 1996 [cited by applicant]
WO 2009145828A2 · 2009 [cited by applicant]
WO 2010057185A1 · 2010 [cited by applicant]
WO 2012027618A2 · 2012 [cited by applicant]
WO 2012027625A2 · 2012 [cited by applicant]
WO 2013123258A1 · 2013 [cited by applicant]
WO 2013173844A1 · 2013 [cited by applicant]
WO 2017087973A1 · 2017 [cited by applicant]
WO 2017087974A1 · 2017 [cited by applicant]
WO 2017087975A1 · 2017 [cited by applicant]
Astruc et al. (2010) Chem. Rev. 110:1857-1959. [cited by applicant]
Baskin et al. (2007) PNAS 104:16793-16797. [cited by applicant]
Eid et al. (2009) Science 323:133-158. [cited by applicant]
Evans (2007) Aus. J. Chem. 60:384-395. [cited by applicant]
Genisphere POC Tech. Note (2012). [cited by applicant]
Kim et al. (2013) Biophys. J. 104:1566-1575. [cited by applicant]
Kolb et al. (2001) Angew. Chem. Int. Ed. Engl. 40:2004-20212. [cited by applicant]
Levene et al. (2003) Science 299:682-686. [cited by applicant]
PubChem CID 11341015. [cited by applicant]
PubChem CID 3514056. [cited by applicant]
Siriporn et al. (2009) ChemComm pp. 806-808. [cited by applicant]
International Search Report and Written Opinion dated Apr. 10, 2017 for related PCT/US2016/063178. [cited by applicant]
Extended European Search Report dated Mar. 21, 2019 for related EP16867352.3. [cited by applicant]
Examination Report dated May 11, 2020 for related EP16867352.3. [cited by applicant]
Examination Report dated Jul. 20, 2021 for related EP16867352.3. [cited by applicant]
Examination Report dated Mar. 1, 2023 for related EP16867352.3. [cited by applicant]
Communication under Rule71(3) EPC dated Jun. 6, 2024 for related EP16867352.3. [cited by applicant]
Decision to grant European patent dated Oct. 17, 2024 for related EP16867352.3. [cited by applicant]
Transmission of patent certificate for related EP16867352.3. [cited by applicant]